JP Morgan Downgrades Intra-Cellular Therapies to Neutral, Raises Price Target to $26

JP Morgan analyst Jessica Fye downgrades Intra-Cellular Therapies (NASDAQ:ITCI) from Overweight to Neutral and raises the price target from $19 to $26.

Benzinga · 01/31/2020 11:35

JP Morgan analyst Jessica Fye downgrades Intra-Cellular Therapies (NASDAQ:ITCI) from Overweight to Neutral and raises the price target from $19 to $26.